Clinical trials: Osteogenesis
Greater Trochanteric Pain Syndrome, GTPS - Greater Trochanteric Pain Syndrome
Evaluation of the Efficacy of the Use MD Tissue Collagen Medical Device in the Infiltrative Treatment of Greater Trochanter Pain Syndrome (GTPS)
Greater Trochanteric Pain Syndrome, also known as GTPS (Greater Trochanteric Pain Syndrome) is a complex clinical condition characterized by chronic and recurrent pain in the lateral region of the hip, near the greater trochanter…
- Conditions
- Greater Trochanteric Pain Syndrome, GTPS - Greater Trochanteric Pain Syndrome, Tendon Disorder, Pertrochanteric Fracture
- Trial name
- MEDANTRO (NCT05486078)
- Testing
- MD Tissue Collagen Medical Device
- Where
- Italy
- Volunteers
- 47 people
- Sponsor
- Guna S.p.a
Osteogenesis Imperfecta
Single Ascending Dose Study of SAR439459 in Adults With Osteogenesis Imperfecta (OI)
SAR439459 is a human anti-Transforming growth factor β (TGFβ) monoclonal antibody. This phase 1 clinical study investigates the safety, tolerability, and activity of a single dose of SAR439459 in adult participants with OI.
- Trial name
- NCT05231668
- Testing
- SAR439459
- Where
- 13 sites in United States, Australia and 2 more
- Volunteers
- 16 people
- Sponsor
- Sanofi
Osteogenesis Imperfecta
Study to Evaluate Romosozumab in Children and Adolescents With Osteogenesis Imperfecta
The primary objective of this study is to evaluate the pharmacokinetics (PK) profile following multiple subcutaneous (SC) doses of romosozumab in children and adolescents with Osteogenesis Imperfecta (OI).
- Trial name
- NCT04545554
- Testing
- Romosozumab, Calcium, Vitamin D
- Where
- 15 sites in United States, Austria and 6 more
- Volunteers
- 25 people
- Sponsor
- Amgen
Fibrodysplasia Ossificans Progressiva (FOP)
A Non-Interventional Study of Clinical Characteristics and Mortality of US Patients With Fibrodysplasia Ossificans Progressiva (FOP)
Primary Objective(s): To describe the demographic characteristics of people living with FOP and a matched cohort of non-FOP people living in the United States (U.S.) To describe the prevalence of clinical characteristics of…
- Trial name
- NCT06064656
- Testing
- Non-Interventional
- Where
- United States
- Volunteers
- 131 people
- Sponsor
- Regeneron Pharmaceuticals
Shoulder Dislocation
Follow-up Study After Bankart Repair Using MG-1
Long term follow-up of patients those who underwent arthroscopic Bankart repair using MG-1 for dislocation of shoulder to evaluate anchor bone hole condition and ossification.
- Trial name
- NCT02228226
- Where
- Japan
- Volunteers
- 11 people
- Sponsor
- Johnson & Johnson K.K. Medical Company
Osteogenesis Imperfecta (OI)
Osteogenesis Imperfecta Trial of AGA2115 for ADUlts With COL1A1 and/or COL1A2 GeNetic Variations (IDUN)
This study will determine the effect of treatment of AGA2115 in adults with Type I, III, or IV osteogenesis imperfecta versus placebo.
- Trial name
- IDUN (NCT07062588)
- Testing
- AGA2115
- Where
- 26 sites in United States, Argentina and 6 more
- Volunteers
- 80 people
- Sponsor
- Angitia Incorporated Limited
Jaw, Edentulous, Partially, Alveolar Bone Loss
Straumann Bone Ceramic Versus BioOss in Sinus Elevation
Straumann Bone Ceramic (SBC) and BioOss will be used as bone grafting materials when there is a need for bone augmentation in the posterior upper jaw. 9 months later the bone formation is evaluated.
- Trial name
- NCT00900822
- Testing
- Straumann Bone Ceramic, BioOss
- Where
- Sweden
- Volunteers
- 11 people
- Sponsor
- Institut Straumann AG
Fibrodysplasia Ossificans Progressiva (FOP)
To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva
This Phase 2, Randomized, Double-Blind, Placebo-Controlled Study is intended to evaluate the Efficacy, Safety, and Tolerability and PK of INCB000928 administered to participants with a clinical diagnosis of fibrodysplasia…
- Trial name
- Progress (NCT05090891)
- Testing
- INCB000928
- Where
- 24 sites in United States, Argentina and 15 more
- Volunteers
- 98 people
- Sponsor
- Incyte Corporation
Osteogenesis Imperfecta
Safety, Pharmacokinetics and Pharmacodynamics of BPS804 in Osteogenesis Imperfecta
This is a randomized, open label intra-patient dose escalation study to evaluate safety and tolerability, pharmacokinetics, and pharmacodynamics of BPS804 in adults with osteogenesis imperfecta (OI).
- Trial name
- NCT01417091
- Testing
- BPS804
- Where
- 6 sites in United States, Belgium and 2 more
- Volunteers
- 10 people
- Sponsor
- Ultragenyx Pharmaceutical Inc
Osteoporosis
GRACE II (General Retrospective Analysis of Commercial Experience With AGN1 LOEP)
The study is designed as a retrospective, multicenter study for subjects previously treated with the AGN1 LOEP Kit in the proximal femur as part of standard hospital practice. This will be a non-randomized and non-blinded study.
- Trial name
- NCT07594639
- Testing
- AGN1 LOEP
- Where
- Belgium
- Volunteers
- 305 people
- Sponsor
- AgNovos Healthcare, LLC
Heterotopic Ossification (HO)
A Study of Andecaliximab in People With Spinal Cord Injury at Risk for Bone Growth Outside of the Normal Skeleton.
This is an open-label study of andecaliximab in participants at risk of developing bone where bone should not be, such as in muscle, tendons, and other soft tissues following traumatic spinal cord injury.
- Trial name
- ANDECA-HO (NCT07024407)
- Testing
- Andecaliximab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Ashibio Inc
Fibrodyplasia Ossificans Progressiva (FOP), Heterotopic Ossification (HO)
Study to Assess the Efficacy and Safety of Garetosmab in Japanese Adult Patients With Fibrodysplasia Ossificans Progressiva (FOP)
The primary safety objective of the study is to assess the safety and tolerability of garetosmab in Japanese male and female adult patients with FOP.
- Trial name
- NCT04577820
- Testing
- garetosmab
- Sponsor
- Regeneron Pharmaceuticals
Multiple Myeloma
Observational Study of the Effects Intravenous Bortezomib Has on Osteoblast (Cell That is Responsible for Bone Formation) Activity in Multiple Myeloma Patients.
The purpose of this study is to measure the markers related to bone metabolism before and after the use of bortezomib injection in patients with multiple myeloma and to evaluate the effect bortezomib injection has on bone disease.
- Trial name
- NCT01026701
- Testing
- bortezomib
- Volunteers
- 104 people
- Sponsor
- Janssen Korea, Ltd., Korea
Fibrodysplasia Ossificans Progressiva
An Efficacy and Safety Study of Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva.
Fibrodysplasia Ossificans Progressiva (FOP) is a rare, severely disabling disease characterized by heterotopic ossification (HO) often associated with painful, recurrent episodes of soft tissue swelling (flare-ups) that lead to…
- Trial name
- MOVE (NCT03312634)
- Testing
- Palovarotene
- Where
- 16 sites in United States, Argentina and 9 more
- Volunteers
- 107 people
- Sponsor
- Clementia Pharmaceuticals Inc.
Achondroplasia
A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia
This is a Phase 3, multicenter, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of infigratinib in children and adolescents with achondroplasia (ACH) who have completed at least 26 weeks of…
- Trial name
- PROPEL3 (NCT06164951)
- Testing
- Infigratinib 0.25 mg/kg/day
- Where
- 27 sites in United States, Argentina and 8 more
- Volunteers
- 114 people
- Sponsor
- QED Therapeutics, a BridgeBio company
Fibrodysplasia Ossificans Progressiva, FOP
A Study to Investigate the Safety, Pharmacokinetics (PK), and Efficacy of Garetosmab in Children and Adolescents With Fibrodysplasia Ossificans Progressiva (FOP)
This study is researching an experimental drug called garetosmab, referred to as "study drug". The study is focused on children and adolescent participants with FOP.
- Trial name
- OPTIMA-2 (NCT07559513)
- Testing
- garetosmab
- Volunteers
- 18 people
- Sponsor
- Regeneron Pharmaceuticals
Fibrodysplasia Ossificans Progressiva
An Open-Label Extension Study of Palovarotene Treatment in Fibrodysplasia Ossificans Progressiva (FOP)
Fibrodysplasia Ossificans Progressiva (FOP) is a rare, severely disabling disease characterized by heterotopic ossification (HO), i.e., abnormal bone formation, often associated with painful, recurrent episodes of soft tissue…
- Trial name
- NCT02279095
- Testing
- Palovarotene dose level 1, Palovarotene dose level 2, Palovarotene dose level 3
- Where
- 8 sites in United States, Argentina and 3 more
- Volunteers
- 58 people
- Sponsor
- Clementia Pharmaceuticals Inc.
Spinal Cord Compression, Spondylosis
UNiD 3D VBR Register
Multicenter study allowing to include the first sixty patients implanted with a custom-made corpectomy implant (UNiD 3D VBR): 30 patient implanted in cervical region and 30 patients implanted in thoracolumbar region.
- Conditions
- Spinal Cord Compression, Spondylosis, Ossification of Posterior Longitudinal Ligament, Spinal Neoplasms
- Trial name
- NCT02926391
- Testing
- UNiD 3D VBR
- Where
- France
- Volunteers
- 12 people
- Sponsor
- Medicrea International
Osteogenesis Imperfecta
Bisphosphonate Treatment of Osteogenesis Imperfecta
The primary purpose of this trial is to evaluate whether the investigational medication is safe, effective and has the ability to increase spine bone density in osteogenesis imperfecta (OI) patients.
- Trial name
- NCT00063479
- Testing
- Zoledronic Acid
- Where
- 10 sites in United States
- Volunteers
- 158 people
- Sponsor
- Novartis Pharmaceuticals
Osteogenesis Imperfecta (OI)
Open-label Extension of Study 20130173 of Denosumab in Children and Young Adults With Osteogenesis Imperfecta
To evaluate long-term safety of denosumab in children/young adults with pediatric osteogenesis imperfecta (OI) who completed the prior study 20130173 (NCT02352753).
- Trial name
- NCT03638128
- Testing
- Denosumab, Alternative osteoporosis medications
- Where
- 22 sites in United States, Australia and 10 more
- Volunteers
- 75 people
- Sponsor
- Amgen